Acepodia Secures $100 Million Series D Financing to Advance First-In-Class Cell Therapies with Antibody-Cell Conjugation (ACC) Platform

Acepodia Announces First Patient Dosed in Phase 1 Clinical Trial of ACE1831, an Anti-CD20 Armed Allogeneic Gamma Delta T-cell Therapy in Development to Treat Patients with Non- Hodgkin’s Lymphoma

PR Newswire

Acepodia to Present Preclinical Data of Gamma Delta T cell Therapy Candidate, ACE2016, an off-the-shelf EGFR-targeting γδ2 T cell therapy against EGFR-expressing solid tumors

PR Newswire

Acepodia to Present Preclinical Data on its Gamma Delta T cell Therapy Candidate, ACE1831, at 2022 SITC Annual Meeting

PR Newswire

Acepodia Congratulates Laureates of the 2022 Nobel Prize in Chemistry and Shares the Excitement to Translate Click Chemistry into a New Class of Investigational Therapies

PR Newswire

Acepodia Announces FDA Clearance of IND Application for ACE1831, an Anti-CD20 Armed Allogeneic gamma delta T-cell Therapy Candidate to Treat Patients with non-Hodgkin's Lymphoma

PR Newswire

Acepodia Raises $109 Million Series C Financing to Advance Development of First-in-Class Antibody Cell Effector Therapies

GlobeNewswire

Acepodia Presents Preclinical Data on its gamma delta T cell Therapy Candidate ACE1831 at 2022 AACR Meeting

Acepodia Announces Expansion of Board of Directors and Scientific Advisory Board

GlobeNewswire

Acepodia Strengthens Board of Directors and Scientific Advisory Board with Key Appointments

GlobeNewswire

Natural Killer Cell Therapy Well Tolerated in Solid Tumors

GeneTherapyLive

Developing Cell Therapies for Solid Tumors and Hematologic Malignancies

GeneTherapyLive